News|Videos|March 28, 2025

RX Review: Impact of New, Upcoming Therapies for ATTR-CM

Name: RX Review: Impact of New, Upcoming Therapies for ATTR-CM
Uploaded: 2025-03-28T12:02:00Z
Duration: 7 min 31 s
Description: RX Review: Impact of New, Upcoming Therapies for ATTR-CM

Author(s)Mazen A. Hanna, MD, Jesus L. Almendral, MD, Marian Vandyck-Acquah, MD

Fact checked by: Patrick Campbell, Victoria Johnson

In this video, part 3 of a 4-part series, panelists discuss the impact of recent approvals and pipeline developments on the outlook for ATTR-CM management.

After more than half a decade with tafamidis (Vyndamax) as the only FDA-approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), the December 2024 and March 2025 approvals of disease-modifying therapies in acoramidis (Attruby) and vutrisiran (Amvuttra) have left clinicians better equipped than ever to meet the needs of this growing patient population.